Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners R&D Solutions

Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners R&D Solutions to Advance Biopharmaceutical Innovations From Leading U.S. Academic Research Institutions

  • Synergy Partners offers significant experience in drug discovery and development. Areas of specialty include R&D strategy, medicinal chemistry, pharmacology, metabolism, drug safety and clinical development.
  • Synergy Partners will provide strategic advice and scientific support to Allied-Bristol Life Sciences’ R&D efforts.

BOSTON (Nov. 18, 2014) - Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned between Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY), today announced that it formed a strategic partnership with Synergy Partners R&D Solutions, LLC.

Read more: Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners R&D Solutions

Allied-Bristol Life Sciences Appoints Former Bristol-Myers Vice President Satish Jindal

Allied-Bristol Life Sciences Appoints Former Bristol-Myers Vice President Satish Jindal to Lead the Discovery of Drug Candidates From Leading Academic Institutions

Boston (October 3, 2014) – Allied-Bristol Life Sciences LLC, a jointly owned enterprise between Allied Minds (LSE: ALM) and Bristol-Myers Squibb Co., today announced that Satish Jindal, Ph.D., formerly Vice President of R&D within Bristol-Myers, has been appointed to lead the company's efforts to identify and foster development of biopharmaceutical innovations from top U.S. university research institutions.

Read more: Allied-Bristol Life Sciences Appoints Former Bristol-Myers Vice President Satish Jindal

Allied Minds and Bristol-Myers Squibb Form New Enterprise to Advance Discoveries

Allied Minds and Bristol-Myers Squibb Form New Enterprise to Advance Discoveries of Biopharmaceutical Innovations at Leading U.S. Academic Research Institutions

Allied-Bristol Life Sciences LLC to identify and speed development of promising science and technologies

Unique collaboration focused on transforming early-stage academic innovation to therapeutic candidates for clinical study

(BOSTON and NEW YORK – Aug 4, 2014) - Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY) today announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S. Allied-Bristol Life Sciences LLC will focus on efficiently and effectively converting discoveries from university research institutions into therapeutic candidates for clinical development, and ultimately approved therapies that address serious diseases. For programs identified by the new enterprise, university researchers will be able to access Bristol-Myers Squibb’s drug discovery research expertise, and Allied Minds’ financial and management experience.

Read more: Allied Minds and Bristol-Myers Squibb Form New Enterprise to Advance Discoveries

Media Contact:
Christine Dunn
ArcPoint Strategic Communications
617.484.1660, x101

Email